Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.31 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14012013 | 1.00 | SMN1; SMN2 (0.36) | SMN1; SMN2SLC1A1SLC7A5KIF11CA1 | |
| Hydrochloric Acid SCHEMBL1067663 | 0.98 | SMN1; SMN2 (0.34) | SMN1; SMN2SLC1A1SLC7A5KIF11CA1 | |
| SCHEMBL8894673 | 0.85 | SMN1; SMN2 (0.42) | SMN1; SMN2SLC1A1SLC7A5KIF11CA1 | |
| SCHEMBL8038311 | 0.80 | ALOX15 (0.41) | SLC1A1SLC7A5ALDH1A1SLC1A3SLC1A2 | |
| SCHEMBL700933 | 0.79 | SLC7A5 (0.56) | SMN1; SMN2SLC7A5CA14SLC1A3SLC1A2 | |
| SCHEMBL76796 | 0.79 | SLC7A5 (0.56) | SMN1; SMN2SLC7A5CA14SLC1A3SLC1A2 | |
| SCHEMBL196338 | 0.79 | SLC7A5 (0.56) | SMN1; SMN2SLC7A5CA14SLC1A3SLC1A2 | |
| SCHEMBL29783468 | 0.79 | SLC7A5 (0.56) | SMN1; SMN2SLC7A5CA14SLC1A3SLC1A2 | |
| SCHEMBL18774951 | 0.78 | CA1 (0.34) | SMN1; SMN2SLC1A1SLC7A5KIF11CA1 | |
| SCHEMBL18774952 | 0.78 | CA1 (0.34) | SMN1; SMN2SLC1A1SLC7A5KIF11CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372527-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2023-11-23 | — | — | US | disclosed |
| US-20230372527-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2023-11-23 | — | — | US | disclosed |
| EP-4225314-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR | AstraZeneca UK Limited (GB) | 2023-08-16 | — | — | EP | disclosed |
| US-11325906-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2022-05-10 | — | — | US | disclosed |
| WO-2022074617-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022074617-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2022-04-14 | — | — | WO | disclosed |
| US-20210040084-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
| WO-2021013735-A1 | PARP1 INHIBITORS | ASTRAZENECA AB (SE) | 2021-01-28 | — | — | WO | disclosed |
| EP-2274297-B1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2012-05-09 | — | — | EP | disclosed |
| EP-2274297-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| CN-1990458-B | Process for preparing 4.4-difluoro-2-amino butyric acid with optical activity and ester thereof | SHANGHAI PHARMATECH CO LTD | 2010-08-11 | — | — | CN | disclosed |
| US-7741327-B2 | Pyrrolidinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
| WO-2009127546-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-22 | — | — | WO | disclosed |
| CN-1990458-A | Process for preparing 4.4-difluoro-2-amino butyric acid with optical activity and ester thereof | SHANGHAI PHARMATECH CO LTD (CN) | 2007-07-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040084-A1 | CHEMICAL COMPOUNDS | CYP11B2, CYP11B1, CYP4B1 | SMN1; SMN2 4768/4885SLC1A1 1773/4885SLC7A5 1581/4885 |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | GCKR, GCK, PDK2 | SMN1; SMN2 2392/4885SLC1A1 1630/4885SLC7A5 1308/4885 |
| US-20230372527-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR | PARP12, PARP11, PARP1 | SMN1; SMN2 3999/4885SLC1A1 3052/4885SLC7A5 3835/4885 |
| US-11325906-B2 | Chemical compounds | CYP11B2, CYP11B1, CYP4B1 | SMN1; SMN2 4768/4885SLC1A1 1773/4885SLC7A5 1581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.